Kowal Investment Group LLC Acquires 6,045 Shares of Pfizer Inc. (NYSE:PFE)

Kowal Investment Group LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 54.8% in the 1st quarter, Holdings Channel reports. The fund owned 17,077 shares of the biopharmaceutical company’s stock after buying an additional 6,045 shares during the period. Kowal Investment Group LLC’s holdings in Pfizer were worth $474,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC increased its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the period. VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.0 %

PFE traded up $0.29 during midday trading on Monday, reaching $28.27. 15,865,726 shares of the company were exchanged, compared to its average volume of 40,708,578. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The company has a market cap of $160.19 billion, a price-to-earnings ratio of -470.42, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company’s fifty day moving average price is $27.90 and its 200 day moving average price is $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm posted $1.23 EPS. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.94%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analysts Set New Price Targets

A number of equities analysts recently commented on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.